Award
National Cancer Institute 5R01CA164719-12
Anti-cancer vaccine targeting the host-parasite interface during fluke infection
Recipient
National Cancer Institute (NCI), part of the National Institutes of Health (NIH)
Award Amount
$151,875.00
Ceiling
$151,875.00
Awarded
September 16, 2025
Identifier
5R01CA164719-12
The National Cancer Institute awarded $151,875 for a project developing an anti-cancer vaccine targeting the parasite Opisthorchis viverrini, linked to cholangiocarcinoma, focusing on host-parasite interface proteins and vaccine efficacy testing in a rodent model.
Description
This project focuses on developing an anti-infection/anti-cancer vaccine targeting proteins essential to the parasite Opisthorchis viverrini, which is prevalent in East Asia and linked to cholangiocarcinoma. The research involves exploring key proteins involved in host-parasite communication and testing vaccine efficacy in a rodent model of human carcinogenesis. The award is managed by the National Cancer Institute, with a total funding of $151,875 for the fiscal year 2025. The project aims to benefit residents of endemic regions in East Asia by providing a novel public health intervention.